Obesity, immunomodulation and chronic kidney disease

Emma Börgeson, Kumar Sharma

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

Original languageEnglish (US)
Pages (from-to)618-624
Number of pages7
JournalCurrent Opinion in Pharmacology
Issue number4
StatePublished - 2013
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Obesity, immunomodulation and chronic kidney disease'. Together they form a unique fingerprint.

Cite this